Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
复制标题
DOI：
10.1186/s12885-018-4925-1
复制
发表时间：
2018-10-29
期刊：
影响因子：
3.8
通讯作者：
Wunderle M
中科院分区：
文献类型：
--
作者：
Gass P;Lux MP;Rauh C;Hein A;Bani MR;Fiessler C;Hartmann A;Häberle L;Pretscher J;Erber R;Wachter DL;Schulz-Wendtland R;Beckmann MW;Fasching PA;Wunderle M
据报道，病理完全应答是三阴性乳腺癌患者无病生存和总体生存的重要替代指标。这项研究调查了三阴性乳腺癌患者对新辅助铂类或基于蒽环类药物的治疗反应和预后的预测因素。2008至2013年间，共有121名三阴性乳腺癌患者接受了铂类或蒽环类药物的新辅助治疗。采用Logistic回归模型，以年龄、临床肿瘤分期、分级和Ki-67作为预测因子和交互作用项，对不同治疗方案的病理完全反应进行评估，以获得调整后的亚组特异性结果。同时分析了病理完全缓解率对无瘤生存率和总生存率的影响。铂/紫杉烷治疗后的病理完全缓解率(50.0%)高于蒽环素/紫杉烷治疗(41.8%)，但在校正分析中差异无统计学意义(OR 1.44；95%CI，0.68~3.09)。组织学分级(G3)越高，铂类药物治疗的病理完全缓解率越高(OR2.27；95%CI，1.00~5.30)。新辅助化疗对病理完全缓解的影响在G1-2组和G3组之间有显著差异(P交互作用 = 0.013)，并且还注意到亚组特异性差异。在接受和不接受铂化疗的两组患者中，病理完全缓解是改善无瘤存活率和总存活率的预测指标。这项对三阴性乳腺癌患者的回顾性研究进一步证明，铂的治疗效果可能最好，特别是在G3肿瘤中。此外，病理完全缓解对预后的影响不依赖于所采用的治疗方法。
It has been reported that pathological complete response is an important surrogate marker for disease-free survival and overall survival in patients with triple-negative breast cancer. This study investigates predictors of the response to neoadjuvant platinum-based or anthracycline-based treatment, and of the prognosis, in patients with triple-negative breast cancer. A total of 121 patients with triple-negative breast cancer received neoadjuvant treatment with either platinum or anthracycline between 2008 and 2013. Pathological complete response was assessed relative to different treatments using logistic regression models with age, clinical tumor stage, grading, and Ki-67 as predictors and interaction terms, to obtain adjusted and subgroup-specific results. The impact of the pathological complete response rate on disease-free survival and overall survival was also analyzed. The pathological complete response rate was higher after platinum/taxane treatment compared with anthracycline/taxane (50.0% vs. 41.8%), but this was not significant in the adjusted analysis (OR 1.44; 95% CI, 0.68 to 3.09). A high histological grade (G3) was a predictor for higher pathological complete response in platinum-based therapy (OR 2.27; 95% CI, 1.00 to 5.30). The effect of neoadjuvant chemotherapy on pathological complete response was significantly different for G1–2 vs. G3 (Pinteraction = 0.013), and additional subgroup-specific differences were noted. Pathological complete response was a predictor for improved disease-free survival and overall survival in both treatment groups, with and without platinum chemotherapy. This retrospective study of patients with triple-negative breast cancer adds to the evidence that the treatment effect of platinum may be greatest particularly in G3 tumors. In addition, the effect of pathological complete response on the prognosis does not depend on the treatment used.
登录
查看更多内容
BRCA1和BRCA2突变载体中乳腺癌和卵巢癌的病理学：BRCA1/2修饰符研究者联盟的结果（CIMBA）。
DOI：
10.1158/1055-9965.epi-11-0775
发表时间：
2012-01
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Mavaddat N;Barrowdale D;Andrulis IL;Domchek SM;Eccles D;Nevanlinna H;Ramus SJ;Spurdle A;Robson M;Sherman M;Mulligan AM;Couch FJ;Engel C;McGuffog L;Healey S;Sinilnikova OM;Southey MC;Terry MB;Goldgar D;O'Malley F;John EM;Janavicius R;Tihomirova L;Hansen TV;Nielsen FC;Osorio A;Stavropoulou A;Benítez J;Manoukian S;Peissel B;Barile M;Volorio S;Pasini B;Dolcetti R;Putignano AL;Ottini L;Radice P;Hamann U;Rashid MU;Hogervorst FB;Kriege M;van der Luijt RB;HEBON;Peock S;Frost D;Evans DG;Brewer C;Walker L;Rogers MT;Side LE;Houghton C;EMBRACE;Weaver J;Godwin AK;Schmutzler RK;Wappenschmidt B;Meindl A;Kast K;Arnold N;Niederacher D;Sutter C;Deissler H;Gadzicki D;Preisler-Adams S;Varon-Mateeva R;Schönbuchner I;Gevensleben H;Stoppa-Lyonnet D;Belotti M;Barjhoux L;GEMO Study Collaborators;Isaacs C;Peshkin BN;Caldes T;de la Hoya M;Cañadas C;Heikkinen T;Heikkilä P;Aittomäki K;Blanco I;Lazaro C;Brunet J;Agnarsson BA;Arason A;Barkardottir RB;Dumont M;Simard J;Montagna M;Agata S;D'Andrea E;Yan M;Fox S;kConFab Investigators;Rebbeck TR;Rubinstein W;Tung N;Garber JE;Wang X;Fredericksen Z;Pankratz VS;Lindor NM;Szabo C;Offit K;Sakr R;Gaudet MM;Singer CF;Tea MK;Rappaport C;Mai PL;Greene MH;Sokolenko A;Imyanitov E;Toland AE;Senter L;Sweet K;Thomassen M;Gerdes AM;Kruse T;Caligo M;Aretini P;Rantala J;von Wachenfeld A;Henriksson K;SWE-BRCA Collaborators;Steele L;Neuhausen SL;Nussbaum R;Beattie M;Odunsi K;Sucheston L;Gayther SA;Nathanson K;Gross J;Walsh C;Karlan B;Chenevix-Trench G;Easton DF;Antoniou AC;Consortium of Investigators of Modifiers of BRCA1/2
通讯作者：
Consortium of Investigators of Modifiers of BRCA1/2
影响因子：
4.8
作者：
Bhattacharyya, A;Ear, US;Bishop, DK
通讯作者：
Bishop, DK
影响因子：
168.9
作者：
Denkert, Carsten;Liedtke, Cornelia;von Minckwitz, Gunter
通讯作者：
von Minckwitz, Gunter
影响因子：
2.7
作者：
Fasching, P. A.;Ekici, A. B.;Beckmann, M. W.
通讯作者：
Beckmann, M. W.
影响因子：
45.3
作者：
Liedtke, Cornelia;Mazouni, Chafika;Pusztai, Lajos
通讯作者：
Pusztai, Lajos